Lin ZL, Xu X, Yang JJ, Lu LQ, Huang H, Hua XZ, Lu LD. Efficacy of budesonide/formoterol inhalation powder in treating viral pneumonia in children. World J Clin Cases 2024; 12(21): 4469-4475 [PMID: 39070822 DOI: 10.12998/wjcc.v12.i21.4469]
Corresponding Author of This Article
Xu Xu, MD, Doctor, Department of Pediatrics, Cangnan Hospital Affiliated to Wenzhou Medical University, No. 2288 Yucang Road, Lingxi Town, Wenzhou 325800, Zhejiang Province, China. xuxu1984_05_05@163.com
Research Domain of This Article
Pediatrics
Article-Type of This Article
Case Control Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Zi-Liang Lin, Xu Xu, Jiao-Jiao Yang, Li-Qiang Lu, Heng Huang, Xiao-Zhen Hua, Li-Dang Lu, Department of Pediatrics, Cangnan Hospital Affiliated to Wenzhou Medical University, Wenzhou 325800, Zhejiang Province, China
Author contributions: Lin ZL designed the study and wrote the first draft; Xu X and Yang JJ completed methodology, data curation, and data analysis; Lu LQ, Huang H, and Hua XZ were responsible for the production of the images; Lu LD revised the paper; All authors have read and approve the final manuscript.
Supported bythe Wenzhou Basic Medical and Health Science and Technology Project, No. Y20210307.
Institutional review board statement: The study protocols were approval by the Ethics Committee of Cangnan Hospital Affiliated to Wenzhou Medical University and performed in accordance with the Declaration of Helsinki.
Informed consent statement: All participants' guardian provided written informed consent to child enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All data generated or analyzed during this study are included in this published article.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xu Xu, MD, Doctor, Department of Pediatrics, Cangnan Hospital Affiliated to Wenzhou Medical University, No. 2288 Yucang Road, Lingxi Town, Wenzhou 325800, Zhejiang Province, China. xuxu1984_05_05@163.com
Received: March 24, 2024 Revised: May 9, 2024 Accepted: May 21, 2024 Published online: July 26, 2024 Processing time: 99 Days and 3.5 Hours
Abstract
BACKGROUND
Respiratory viruses are increasingly detected in children with community-acquired pneumonia. Further strategies to limit antibiotic use in children with viral pneumonia are warranted.
AIM
To explore clinical efficacy of budesonide/formoterol inhalation powder for viral pneumonia in children and its impact on cellular immunity and inflammatory factor production.
METHODS
A total of 60 children with viral pneumonia were recruited: 30 receiving budesonide/formoterol inhalation powder and 30 conventional symptomatic treatment. Outcome measures included peripheral blood levels of inflammatory cytokines, CD4+, CD8+, Th1, Th2, Th17 and Treg, clinical efficacy, and incidence of adverse reactions.
RESULTS
Compared with the control group, the observation group showed a significant reduction in interleukin-6 and high-sensitivity C-reactive protein levels after treatment. Compared with the control group, the observation group showed a significant increase in CD4+/CD8+ and Th1/Th2 levels, and a decrease in Th17/Treg levels after treatment. The total effective rates in the observation group and the control group were 93.75% and 85.00%, respectively, which was a significant difference (P = 0.003).
CONCLUSION
Budesonide/formoterol inhalation powder significantly improved therapeutic efficacy for viral pneumonia in children. The mechanism of action may be related to downregulation of the inflammatory response and improved cellular immune function.
Core tip: Treatment with budesonide/formoterol inhalation powder can significantly improve the efficacy of treatment of viral pneumonia in children. The mechanism of action may be related to downregulation of the inflammatory response and improvement of cellular immune function.
